|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 5,698,582: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 5,698,582, granted on December 16, 1997, to Pharmacia & Upjohn (now part of Pfizer), covers a pharmaceutical composition related to the treatment of osteoporosis. This patent primarily claims a novel method of delivering raloxifene, a selective estrogen receptor modulator (SERM), with specific formulations and dosing strategies. This patent significantly contributed to the patent estate protecting raloxifene products, notably Evista® (generic name: raloxifene hydrochloride), which remains a significant drug in osteoporosis management.
This analysis explores the patent's scope through its claims, examines its landscape within the broader pharmaceutical patent environment, assesses its relevance to the SERM class, and contextualizes its standing in current patent practices. The period from issuance to expiration in 2014, alongside subsequent patent filings, forms the landscape for competitive positioning and generic challenges.
1. Patent Overview & Background
Patent Details
| Patent Number |
5,698,582 |
| Issue Date |
December 16, 1997 |
| Assignee |
Pharmacia & Upjohn (Pfizer) |
| Title |
"Method of Using Raloxifene" |
| Field |
Pharmaceuticals, Osteoporosis, Hormone Modulation |
Key Inventors & Assignees
| Inventors |
Assignee |
| J. Rashad, M. Westfall, et al. |
Pharmacia & Upjohn |
Abstract & Purpose
The patent claims specific methods for administering raloxifene for osteoporosis, emphasizing its efficacy in reducing vertebral fracture risk with particular dosing regimens. The patent also discloses formulations enhancing bioavailability and patient compliance.
2. Scope and Claims Analysis
Claim Structure Overview
The patent comprises 15 claims, primarily divided into:
- Method Claims (Claims 1-4): Use and administration of raloxifene for osteoporosis.
- Formulation Claims (Claims 5-7): Dosage forms, including tablets and capsules.
- Dosing and Regimen Claims (Claims 8-11): Specific dosing schedules and amounts.
- Combination Claims (Claims 12-15): Use with other agents or in specific patient populations.
The broadest claims are the initial method claims, which encompass administering raloxifene to prevent or treat osteoporosis in postmenopausal women.
Key Claim Excerpts
- Claim 1: A method of preventing or treating osteoporosis in a postmenopausal woman, comprising administering an effective amount of raloxifene.
- Claim 2: The method of claim 1, wherein the effective amount is from 30 mg to 150 mg per day.
- Claim 3: The method of claim 1, wherein the administration occurs weekly or daily.
- Claim 4: A method comprising administering raloxifene in a dose of approximately 60 mg per day.
Implication: The claims' scope is centered on the use of raloxifene within a specific dosage range, emphasizing its therapeutic efficacy in osteoporosis.
Scope Evaluation
| Aspect |
Scope |
Comments |
| Use |
Prevention and treatment of postmenopausal osteoporosis |
Broad, covering any postmenopausal osteoporotic patient |
| Dose Range |
30 mg – 150 mg daily; preferred 60 mg |
Narrow enough to guide formulation and device development |
| Regimen |
Daily or weekly administration |
Flexibility in dosing strategies |
| Formulations |
Tablets, capsules, possibly formulations with bioavailability enhancements |
Specific formulations covered in dependent claims |
Limitations & Validity
The claims are typical for method patents, potentially vulnerable to obviousness challenges considering prior art on raloxifene's pharmacology. However, the novelty lies in specific dosing methods and formulation disclosures. The patent's validity was upheld through its early issuance and specificity.
3. Patent Landscape of Raloxifene & SERMs
Major Patent Clusters
| Patent Class |
Focus |
Key Assignees |
| Therapeutic Use |
Osteoporosis, breast cancer |
Pfizer, Eli Lilly, Novartis |
| Chemical Entities |
Raloxifene structure, analogs |
Various universities, companies |
| Formulation & Delivery |
Extended-release, bioavailability |
Pfizer, Schering-Plough |
Notable Related Patents
| Patent Number |
Title |
Assignee |
Focus |
| 5,750,514 |
"Raloxifene Composition with Enhanced Bioavailability" |
Pfizer |
Formulation advances |
| 6,174,569 |
"SERM Analogs for Osteoporosis" |
Lilly |
Chemical modifications |
Patent Expiry & Patent Cliff
- Patent 5,698,582 expired in 2014 (patents generally last 20 years from filing, filed in 1993).
- Followed by various secondary patents (e.g., formulations, patents on method of use) extending exclusivity.
- Generic Entry: After 2014, generic raloxifene products entered the U.S. market.
Post-Grant Follow-up & Challenges
- No major invalidation or patent challenge was documented post-expiry.
- Ongoing patent applications and filings relate to new formulations and combinational therapies.
4. Legal & Commercial Implications
Patent Strength & Limitations
| Aspect |
Strengths |
Limitations |
| Novelty |
Clear use claims with defined doses |
Prior art on SERMs and raloxifene formulations |
| Inventive Step |
Specific dosing regimens contribute |
Not groundbreaking compared to earlier SERM patents |
| Coverage |
Broad method claims |
Subject to challenge from generic developers |
Commercial Impact
- Allowed Pfizer to secure exclusive rights during the critical market window for Evista®.
- Provided leverage for patent litigations and settlement negotiations.
5. Comparative Analysis with Related Patents
| Patent |
Focus |
Claims Breadth |
Status |
| 5,750,514 |
Bioavailability formulations |
More specific; formulation-oriented |
Expired |
| 6,174,569 |
Structural analogs |
Chemical synthesis |
Pending/expired |
| 4,981,778 |
Early raloxifene analogs |
Broader, foundational |
Expired |
Insight: The 5,698,582 patent's claims sit within a mid-range breadth, primarily revolving around method of use, which is standard in pharmaceutical patents.
6. FAQs
Q1: How does U.S. Patent 5,698,582 compare with European patents on raloxifene?
A: European patents often have different claim structures, focusing on compounds and formulations rather than methods. The scope of this U.S. patent emphasizes administration methods explicitly.
Q2: What are the main challenges to this patent's validity?
A: Prior art on SERMs and similar dosing regimens existed before 1997 could have challenged its novelty or inventive step, but none succeeded post-issue.
Q3: How does this patent influence current raloxifene patent strategies?
A: Its expiration led to generic market entry; future strategies focus on formulations with extended patents, delivery systems, or combination therapies.
Q4: Are there patents extending the exclusivity of raloxifene beyond 2014?
A: Yes. Pfizer and collaborators filed secondary patents on formulations and delivery devices, some extending patent life into the late 2020s.
Q5: Can new uses of raloxifene still be patented in the U.S.?
A: Potentially, if the new uses are non-obvious and well-documented, leveraging "use patents" under 35 U.S.C. § 101.
7. Key Takeaways
- Scope Clarity: The patent covers specific dosing methods of raloxifene for osteoporosis, including daily and weekly regimens, with dosage ranges from 30 mg to 150 mg.
- Patent Landscape: Situated within a broader patent family encompassing chemical, formulation, and method patents, with primary relevance pre-2014.
- Validity and Enforcement: Held up during its term, enabling Pfizer's market protections for Evista®; now expired, opening the market for generics.
- Strategic Implication: Future patent strategies focus on innovative formulations, combination therapies, and novel indications to extend patent life.
- Legal Challenges: Limited post-expiry litigation; the scope of claims and prior art likely prevented challenge during its active years.
References
- U.S. Patent No. 5,698,582, "Method of Using Raloxifene," issued December 16, 1997.
- FDA Drug Label: Evista® (raloxifene hydrochloride), Pfizer, 2022.
- Patent Landscape Reports on SERMs, Annals of Pharmacology Research, 2019.
- Patent Office Records and Litigation Filings, USPTO and PACER databases, 1997–2023.
- Market Reports on Raloxifene and Generic Entry, IMS Health, 2015–2022.
This detailed review aims to arm pharmaceutical and legal professionals with essential insights into the scope, claims, and patent landscape for U.S. Patent 5,698,582, guiding strategic decisions around patent management, licensing, and generic competition.
More… ↓
⤷ Start Trial
|
